Zacks Investment Research upgraded shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) from a hold rating to a buy rating in a research report report published on Thursday. Zacks Investment Research currently has $1.25 price target on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley restated a buy rating and issued a $4.00 price objective on shares of Ekso Bionics Holdings in a research report on Monday, May 15th.
Ekso Bionics Holdings (EKSO) traded down 2.61% during midday trading on Thursday, reaching $1.12. 594,918 shares of the company’s stock were exchanged. The firm’s market capitalization is $28.88 million. The firm’s 50 day moving average is $1.54 and its 200 day moving average is $2.27. Ekso Bionics Holdings has a 52 week low of $0.99 and a 52 week high of $6.38.
In other Ekso Bionics Holdings news, insider Russ Angold sold 221,746 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $1.55, for a total value of $343,706.30. Following the sale, the insider now owns 400,678 shares in the company, valued at approximately $621,050.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 259,352 shares of company stock worth $399,373. Insiders own 7.10% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Intellectus Partners LLC boosted its position in Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after purchasing an additional 5,294 shares in the last quarter. Independence Advisors LLC purchased a new stake in Ekso Bionics Holdings in the 2nd quarter worth approximately $1,840,000. Carl Domino Inc boosted its position in Ekso Bionics Holdings by 74.7% in the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after purchasing an additional 35,088 shares in the last quarter. National Planning Corp boosted its position in Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after purchasing an additional 126,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after purchasing an additional 176,197 shares in the last quarter. Institutional investors and hedge funds own 6.04% of the company’s stock.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.